BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Theratechnologies Inc. (TH.TO) Presents Results From a Pharmacokinetic/Phamacodynamic Evaluation of Tesamorelin at the Endocrine Society's Annual Meeting


6/15/2009 11:36:50 AM

MONTREAL, CANADA--(Marketwire - June 12, 2009) - Theratechnologies (TSX: TH) announced today that results from a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tesamorelin were presented as a poster (Poster number: P3-641) at the Endocrine Society's 91st Annual Meeting in Washington D.C. Tesamorelin is an analogue of the growth hormone releasing factor evaluated for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

The poster outlined the results of two Phase 1 studies performed to determine the PK/PD profiles of tesamorelin after single and multiple administrations of 2 mg of tesamorelin once daily for 14 consecutive days, in healthy volunteers and HIV-positive patients receiving a stable antiretroviral regimen. The results showed that tesamorelin's PK/PD profiles were generally similar in both groups and suggest that there is a minimal impact on tesamorelin's PK parameters and on the induction of the insulin-like growth factor (IGF-1) when tesamorelin is given to HIV-positive patients on antiretroviral therapy.

Levels of IGF-1 at baseline were within normal range and comparable in both groups (healthy: 175 ng/mL; HIV+: 164 ng/mL). After 14 days of daily injection, a similar increase was observed in healthy volunteers and in HIV-positive patients (115% and 121%, respectively, compared to baseline). In both studies, the extent of absorption (AUC) and the maximal concentration (Cmax) were similar (approximately 700 pgï¿1/2h/mL and 2400 pg/ml for AUC and Cmax, respectively). The half-life of tesamorelin ranged between 13 to 38 minutes in both healthy volunteers and HIV-positive patients.

The poster presented is now available on Theratechnologies' website at www.theratech.com

About HIV-Associated Lipodystrophy

Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. The Company has also entered into a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a NDA recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to, information regarding the beneficial nature of tesamorelin for patients. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or variations of them denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the risk that the results from treatment with tesamorelin may vary from one patient to another.

The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http:/www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.


Contacts:
Theratechnologies Inc.
Aline Vandermeer
Coordinator, IR & Communications
514-336-7800, ext. 229
avandermeer@theratech.com
www.theratech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES